This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here.  Adverse event reporting information can be found at the bottom of the page.

PALOMA-2 Trial

Confidence In A Treatment that’s Setting The Standard1-2

Primary results from a Phase III trial of IBRANCE® plus letrozole compared with placebo plus letrozole in post-menopausal women with endocrine receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) locally advanced and metastatic breast cancer.1,2​​​​​​​​​​​​​​

Study Design

Study design and patient populations for the phase III PALOMA-2 Trial


Efficacy Outcomes

Efficacy outcomes including mPFS, tumour response rates and delay to chemotherapy​​​​​​​


Quality of Life Outcomes

FACT-B Quality of Life outcomes​​​​​​​


Safety Profile

IBRANCE® safety and frequently reported adverse events


IBRANCE® Mode of Action

Dual inhibition with endocrine therapy


IBRANCE® Real World Evidence

Real-world evidence for IBRANCE® (palbociclib) in advanced Breast Cancer

Read more

AI : Aromatase Inhibitor, ER+ : Oestrogen Receptor-positive, ET : Endocrine Therapy, HER2- : Human Epidermal growth factor Receptor 2-negative, HR+ : Hormone Receptor-positive, LHRH : Luteinising Hormone-Releasing Hormone, mBC :  metastatic Breast Cancer

  1. Rugo HS, et al. Breast Cancer Res Treat. 2019;174:719–29.
  2. Finn RS, et al. N Engl J Med. 2016;375:1925-1936.
PP-IBR-GBR-4072. February 2022

PALOMA-2 Trial

IBRANCE® + Aromatase Inhibitor (AI) Clinical Trial Results

  • Study Design
  • Efficacy Outcomes
  • Quality of Life Outcomes
  • Safety Profile
  • IBRANCE® Mode of Action

Clinical Trials

  • Clinical Trial results for IBRANCE®
  • IBRANCE® Clinical Trials
  • PALOMA-2 Trial

    ​​​​​​​PALOMA-3 Trial


This text is for block level content. P tags can go in here too


IBRANCE® safety information and outcomes

  • IBRANCE® Safety Profile
  • Neutropenia
  • Adverse Event Management


  • IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

Ask Pfizer

Connect virtually with a Pfizer representative to discuss promotional information on a selected range of products.

Book now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?